BUZZ-Supernus rises after FDA approves its drug-device combination for Parkinson's disease

Reuters
05 Feb
BUZZ-Supernus rises after FDA approves its drug-device combination for Parkinson's disease

** Shares of Supernus Pharmaceuticals SUPN.O rise 6.2% to $39.67

** SUPN says U.S. FDA has approved its drug-device combination, Onapgo, to treat movement-related symptoms of Parkinson's disease

** Approval comes after previous declines in 2022 and 2024 due to quality and device concerns

** SUPN says Onapgo will be available in United States in Q2 and is expected to generate $200 mln to 300 mln in peak sales

** SUPN gained 30.4% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10